Comparative Pharmacology
Head-to-head clinical analysis: DOXY LEMMON versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY LEMMON versus OXYTETRACYCLINE HYDROCHLORIDE.
DOXY-LEMMON vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg orally or intravenously once daily.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
Terminal elimination half-life: 18-22 hours (mean ~20 hours) in adults with normal renal function. Clinically, this supports twice-daily dosing; prolonged in severe renal impairment (up to 40-60 hours) or hepatic impairment.
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Renal (approx. 40% as unchanged drug via glomerular filtration), biliary/fecal (approx. 60% as active and inactive metabolites, with significant enterohepatic recycling). Dose adjustment not required in mild renal impairment, but caution in severe hepatic dysfunction.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic